Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
ALXN1720 for Myasthenia Gravis
Recruiting1 awardPhase 3
Charlotte, North Carolina
This trial is testing a new medication called ALXN1720 to help adults with a type of muscle weakness caused by their immune system. The medication aims to stop the immune system from attacking their muscles, which should help reduce their symptoms.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service